Syndicate content

Milestone of Stem-Cell-Derived Exosome Program Achieved by Avalon Globocare Corp; Will Allow Company to Enter Its Next Phase of Commercializing Clinical-Grade Exosome Products; Skin Care and Wound-Healing Products Will Be First Developed

On June 10, 2019, Avalon GloboCare Corp. (AVCO), a leading global developer of cell-based technologies and therapeutics, announced it has achieved a major milestone in bio-production standardization of clinical-grade stem-cell-derived exosomes. The standardized procedure was a direct result of the previously announced co-development program (https://ir.avalon-globocare.com/press-releases/detail/28/avalon-globocar...) at Weill Cornell Medicine with Yen-Michael Hsu, MD, PhD, as principal investigator. The process has been co-developed and operated within Weill Cornell's cGMP-certified cell therapy facility jointly accredited under the Foundation of Accreditation for Cellular Therapy (FACT), American Association of Blood Banking (AABB), College of American Pathologists (CAP), as well as Clinical Laboratory Improvement Amendment (CLIA). Avalon will hold a press conference to announce the launch of its exosome product commercialization plan, including a series of over-the-counter skincare and wound-healing products with Avalon's Clinical-Grade Tissue-Specific EXosomes as additives (ACTEX), on June 15, 2019 during the 2nd International Aesthetic Industry Conference in Chengdu, China -- the largest conference of its kind in Asia. In addition to product commercialization, this standardization of clinical-grade stem-cell-derived exosomes will lead to parallel development of Avalon's clinical programs, including AVA-202 and AVA-203, for angiogenic/orthopedic regeneration, as well as treatment of fibrotic diseases. "We are pleased to complete such a significant developmental milestone of our exosome program," stated David Jin, MD, PhD, CEO and President of Avalon GloboCare and Co-CEO of its subsidiary GenExosome Technologies. "As a result, we look forward to an accelerated pathway of our exosome-based clinical programs for regenerative therapeutics, as well as exosome product commercialization," added Dr. Jin. Avalon GloboCare Corp. (AVCO) is a leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics (''liquid biopsy''), cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.

[Press release] [Yahoo Finance News article]